Home Newsfeeds Needham Maintains Buy on Perficient, Lowers Price Target to $85

Needham Maintains Buy on Perficient, Lowers Price Target to $85

Needham analyst Mayank Tandon maintains Perficient (NASDAQ:PRFT) with a Buy and lowers the price target from $95 to $85.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Needham analyst Mayank Tandon maintains Perficient (NASDAQ:PRFT) with a Buy and lowers the price target from $95 to $85.

Truist Securities Maintains Buy on Diamondback Energy, Raises Price Target to $203

By Benzinga Newsdesk

July 19, 10:17 AM

Truist Securities analyst Neal Dingmann maintains Diamondback Energy (NASDAQ:FANG) with a Buy and raises the price target from $185 to $203.

FANG

US, China Will Determine War And Peace, Says Singapore’s Ex-Foreign Minister: ‘Taiwan Is Only A Piece On The Chessboard’

By Navdeep Yadav

August 28, 12:54 AM

The future of Taiwan is largely dependent on the dynamics between the U.S. and China, said George Yeo, former Foreign Minister of Singapore.

AAPL

Analyst Ratings

Evaluating Mid-America Apartment: Insights From 9 Financial Analysts

By Benzinga Insights

April 29, 12:00 PM

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Mid-America Apartment…

MAA

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

By Vandana Singh

April 16, 1:32 PM

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.

CGEM

Needham Maintains Buy on Perficient, Lowers Price Target to $85

Related Posts

Truist Securities Maintains Buy on Diamondback Energy, Raises Price Target to $203

US, China Will Determine War And Peace, Says Singapore’s Ex-Foreign Minister: ‘Taiwan Is Only A Piece On The Chessboard’

Evaluating Mid-America Apartment: Insights From 9 Financial Analysts

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity